| ID | 10046 |
| Vaccine Name | JCOVDEN |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Non-replicating viral vector |
| Vaccine Status | Approved |
| Manufacturer | Janssen Vaccines & Prevention B.V. |
| Year of Manufacturing | NA |
| Manufacturing Country | Leiden, Netherlands |
| Age | NA |
| Dosage | NA |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | NA |
| Description | Recombinant replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding Spike protein antigen of the SARS-CoV-2 |
| Approving Organisation | EMA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | Ad26.COV2.S, JNJ-78436735,Ad26COVS1, VAC31518,COVID-19 Vaccine Janssen,Johnson & Johnson COVID‑19 vaccine |
| PMID | NA |
| Clinical Trial ID | NA |
| Reference Link | https://extranet.who.int/pqweb/sites/default/files/documents/Status_of_COVID-19_Vaccines_within_WHO_EUL-PQ_evaluation_process-16June2021_Final.pdf |
| Additional Links | NA
|